Zynerba Pharmaceuticals Gets Approval From the FDA for its Zygel CBD Topical

Zynerba Pharmaceuticals Gets Approval From the FDA for its Zygel CBD Topical

Original Source: Synthetic CBD from Main Line biotech gets fast track status from FDA

Zynerba Pharmaceuticals of Devon announced Monday morning that it had won the status for its Zygel transdermal CBD lotion. Fast Track designation speeds up the review of drugs that treat an unmet medical need. There currently are no drugs to treat the symptoms of Fragile X syndrome, which include developmental problems from learning disabilities to cognitive impairment. Zynerba is in the final stages of a clinical trial of Zygel and hopes to have it on the market by late 2020, said spokesman Will Roberts.

This article was republished on CBDNewsFeed.com from the original article, Synthetic CBD from Main Line biotech gets fast track status from FDA, which was originally published on 2019-05-06 13:45:00 (based on the date that was listed on the original article at the time it was republished). We shared this article on CBDNewsFeed.com because our editorial staff believed that its context was useful and helpful to our readers. If you have any questions regarding this article, please email us at .

Thank you for reading this article! We’d love to hear your thoughts and answer your questions in the comments below.

Leave a Reply

avatar
  Subscribe  
Notify of